TY - JOUR
T1 - Whole-brain radiotherapy for brain metastases
T2 - Evolution or revolution?
AU - Brown, Paul D.
AU - Ahluwalia, Manmeet S.
AU - Khan, Osaama H.
AU - Asher, Anthony L.
AU - Wefel, Jeffrey S.
AU - Gondi, Vinai
N1 - Publisher Copyright:
© 2017 by American Society of Clinical Oncology.
PY - 2018/2/10
Y1 - 2018/2/10
N2 - An estimated 20% of patients with cancer will develop brain metastases. Approximately 200,000 individuals in the United States alone receive whole-brain radiotherapy (WBRT) each year to treat brain metastases. Historically, the prognosis of patients with brainmetastases has been poor; however, with new therapies, this is changing. Because patients are living longer following the diagnosis and treatment of brain metastases, there has been rising concern about treatment-related toxicities associated with WBRT, including neurocognitive toxicity. In addition, recent clinical trials have raised questions about the use ofWBRT. To better understand this rapidly changing landscape, this review outlines the treatment roles and toxicities of WBRT and alternative therapies for the management of brain metastases.
AB - An estimated 20% of patients with cancer will develop brain metastases. Approximately 200,000 individuals in the United States alone receive whole-brain radiotherapy (WBRT) each year to treat brain metastases. Historically, the prognosis of patients with brainmetastases has been poor; however, with new therapies, this is changing. Because patients are living longer following the diagnosis and treatment of brain metastases, there has been rising concern about treatment-related toxicities associated with WBRT, including neurocognitive toxicity. In addition, recent clinical trials have raised questions about the use ofWBRT. To better understand this rapidly changing landscape, this review outlines the treatment roles and toxicities of WBRT and alternative therapies for the management of brain metastases.
UR - http://www.scopus.com/inward/record.url?scp=85041901663&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041901663&partnerID=8YFLogxK
U2 - 10.1200/JCO.2017.75.9589
DO - 10.1200/JCO.2017.75.9589
M3 - Review article
C2 - 29272161
AN - SCOPUS:85041901663
SN - 0732-183X
VL - 36
SP - 483
EP - 491
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 5
ER -
